Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs: Effect of bile duct cannulation on excretion pathways

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1231-1240

  Dalvie, Deepak K ^a   Khosla, Natasha B ^a   Navetta, Kimberly A ^a   Brighty, Katherine E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT; CANNULATION; CONTROLLED STUDY; DOG; DRUG ACETYLATION; DRUG BILE LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; MALE; MASS SPECTROMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; BILE DUCTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; FLUOROQUINOLONES; MALE; MASS SPECTROMETRY; NAPHTHYRIDINES; RADIOMETRY; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0030471095     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. T. D. Gootz, K. E. Brighty, M. R. Anderson, B. J. Schmeider, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3,1,0]hexyl)naphthyridone antimicrobial. Diagn. Microbiol. Infect. Dis. 19, 235-243 (1994).
2. B. Briggs Gooding and R. N. Jones: In vitro antimicrobial activity of CP-99,219, a novel 7-azabicyclonaphthyridone. Antimicrob. Agents Chemother. 37, 349-353 (1993).
3. T. D. Gootz and P. R. McGuirk: New quinolones in development. Expert. Opin. Invest. Drugs 3, 93-114 (1994).
4. R. Teng, D. Girard, T. D. Gootz, G. Foulds, and T. E. Liston: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone in rats, dogs and monkeys. Antimicrob. Agents Chemother, 40, 561-566 (1996).
5. 14C]CP-99,219 into gastric tissue of Long-Evans rats and Swiss-Webster mice following intravenous administration. In "Program and Abstracts of the 7th European Congress of Clincal Microbiology and Infectious Diseases," p. 3. Vienna, Austria, 1995.
6. R. Teng, S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36, 385-394 (1995).
7. L. A. Wheeler, F. B. Soderberg, and P. Goldman: Reduction of N-hydroxy-4-acetylaminobiphenyl by intestinal microflora of the rat. Cancer Res. 35, 2962-2968 (1975).
8. K. M. Straub, P. Rudewicz, and C. Gravie: Metabolic mapping of drugs: rapid screening techniques for xenobiotic metabolites with MS/MS techniques. Xenobiotica 17, 413-422 (1987).
9. P. J. Jackson, R. D. Brownsill, A. R. Taylor, and B. Walther: Use of electrospray ionization and neutral loss liquid chromatography/tandem mass spectrometry in drug metabolism studies. J. Mass Spectrom. 30, 446-451 (1995).
10. J. J. Vrbanac, I. A. O'Leary, and J. Baczynsky: Utility of the parent-neutral loss scan screening technique: partial characterization of urinary metabolites of U-78875 in monkey urine. Biol. Mass Spectrom. 21, 517-522 (1992).
11. P. Rudewicz and K. M. Straub: Rapid structure elucidation of catecholamine conjugates with tandem mass spectrometry. Anal. Chem. 58, 2928-2934 (1986).
12. R. F. Stack and P. J. Rudewicz: Comparison of thermospray and electrospray for the analysis of the conjugates of the androgen receptor antagonist zanoterone. J. Mass Spectrom. 30, 857-866 (1995).
13. E. M. Faed: Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15, 1213-1249 (1984).
14. F. W. Janssen, S. K. Kirkman, C. Fenselau, M. Stiogniew, B. R. Hofmann, E. W. Young, and H. W. Ruelius: Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Drug Metab. Dispos. 10, 599-604 (1982).
15. M. L. Hyneck, A. Munafo, and L. Z. Benet: Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab. Dispos. 16, 322-324 (1988).
16. K. Sudo, O. Okazaki, M. Tsumura, and H. Tachizawa: Isolation and identification of metabolites of ofloxacin in rats, dogs and monkeys. Xenobiotica 16, 725-732 (1986).
17. K. Iwasaki, T. Shiraga, K. Noda, K. Tada, and H. Noguchi: Terminal N-sulfoconjugation of an alicyclic amine (piperazine) identified as a new metabolite of tiaramide in mouse and rat. Xenobiotica 13, 273-278 (1983).
18. K. Iwasaki, T. Shiraga, K. Noda, K. Tada, and H. Noguchi: N-Sulfoconjugation of alicyclic, alkyl- and arylamines in vivo and in vitro. Xenobiotica 16, 651-659 (1986).
19. W. Gau, J. Kurz, U. Peterson, H. J. Ploshke, and C. Wuensche: Isolation and structural elucidation of urinary metabolites of ciprofloxacin. Arzneim. Forsch. 36, 1545-1549 (1986).
20. K. Straub, M. Davis, and B. Hwang: Benzazepine metabolism revisited. Drug Metab. Dispos. 16, 359-366 (1988).
21. C. D. Klaassen and J. B. Watkins III: Mechanisms of bile formation, hepatic uptake and biliary excretion. Pharmacol. Rev. 36, 1-67 (1984).
22. A. M. Hoyumpa, Jr., and S. Schenker: Influence of liver diseases on the disposition and elimination of drugs. In "Diseases of the Liver" (L. Schiff and E. R. Schiff, eds.), pp. 709-746. J. B. Lippincott Co., Philadelphia, 1982.
23. C. D. Klaassen: Bile flow and composition during bile acid depletion and administration. Can. J. Physiol. Pharmacol. 29, 334-348 (1974).
24. R. F. Mayol, C. A. Cole, G. M. Luke, K. L. Colson, and E. H. Kerns: Characterization of the metabolites of the antidepressant drug nefazadone in human urine and plasma. Drug Metab. Dispos. 22, 304-311 (1994).
25. A. Y. Mak and D. C Swinney: 17-O-Acetyltestosterone formation from progesterone in microsomes from pig testes: evidence for the Baeyer-Villiger rearrangement in androgen formation catalyzed by CYP 17. J. Am. Chem. Soc. 114, 8309-8310 (1992).
26. G. M. Lower, Jr., and G. T. Bryan: Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem. Pharmacol. 22, 1581-1588 (1973).
27. M. R. Jachau: Species differences in drug metabolism. In "Comprehensive Medicinal Chemistry" (J. B. Taylor, ed.), pp. 219-235. Pergamon Press, New York, 1990.
28. B. R. Goldin: Intestinal microflora: metabolism of drugs and carcinogens. Ann. Med. 22, 43-48 (1990).
29. B. S. Drasar and M. J. Hill: "Human Intestinal Microflora," pp. 72-102. Academic Press, New York, 1974.
30. F. Okumura, O. Udea, S. Kitamura, and K. Tatsumi: N-Acetylation and N-formylation of carcinogenic amines and related compounds in dogs. Cardnogenesis (Lond.) 16, 71-76 (1995).
31. B. J. Dull, K. Salata, and P. Goldman: Role of intestinal flora in acetylation of sulfasalzine metabolites. Biochem. Pharmacol. 36, 3772-3774 (1987).
32. F. Okumura, S. Kitamura, and K. Tatsumi: N-Acylation of arylamines in dogs. J. Pharmacobio-Dyn. 14, S-47 (1991).